OBJECTIVE: To study the presence of 1,2-dicarbonyl compounds in peritoneal dialysis (PD) fluids, their concentration in effluents with increasing dwell time, and their role in the formation of advanced glycation end-products (AGEs). MEASUREMENTS: Dicarbonyl compounds in heat- and filter-sterilized PD fluids were quantified by reverse-phase high performance liquid chromatography (HPLC) after derivatization to dimethoxyquinoxaline derivatives. Kinetics of the in vitro formation of AGEs upon incubation of 1,2-dicarbonyl compounds or PD fluids with albumin, with or without aminoguanidine, were measured by AGE fluorescence (excitation/emission wavelengths of 350 nm/430 nm). PATIENTS: AGEs and dicarbonyl compounds were measured in effluents collected from standardized 4-hour dwells from 8 continuous cycling peritoneal dialysis patients. RESULTS: In PD fluids, 3-deoxyglucosone (3-DG) has been identified as the major dicarbonyl compound formed during the process of heat sterilization. The process also formed glyoxal (GO) and methylglyoxal (MGO), with the amount of 3-DG being approximately 25-60 times higher than GO and MGO. When incubated with albumin, the identified 1,2-dicarbonyl compounds rapidly formed AGEs. The formation of AGEs was more pronounced in conventional heat-sterilized PD fluids compared with filter-sterilized PD fluids, and was completely inhibited by aminoguanidine. In effluents, the concentration of MGO, GO, and 3-DG decreased with increasing dwell time, with a concomitant increase in AGE fluorescence. CONCLUSIONS: The dicarbonyl compounds 3-DG, MGO, and GO are potent promoters of AGE formation. The presence of these and possibly other dicarbonyl compounds formed during heat sterilization of glucose-based PD fluids is, to a large extent, responsible for the in vitroAGE formation by these fluids, as evidenced by the speed of AGE formation in PD fluids and the complete inhibition by aminoguanidine. Because 3-DG, MGO, and GO are rapidly cleared from PD fluids during dialysis, these compounds may contribute to the in vivo AGE formation in PD patients.

This article has been cited by other articles:

				B. Santamaria, A. C. Ucero, A. Reyero, R. Selgas, M. Ruiz-Ortega, M. Catalan, J. Egido, and A. Ortiz 3,4-Dideoxyglucosone-3-ene as a mediator of peritoneal demesothelization Nephrol. Dial. Transplant., June 3, 2008; (2008) gfn273v1. [Abstract] [Full Text] [PDF]

				R. K. Schindhelm, M. Alssema, P. G. Scheffer, M. Diamant, J. M. Dekker, R. Barto, G. Nijpels, P. J. Kostense, R. J. Heine, C. G. Schalkwijk, et al. Fasting and Postprandial Glycoxidative and Lipoxidative Stress Are Increased in Women With Type 2 Diabetes Diabetes Care, July 1, 2007; 30(7): 1789 - 1794. [Abstract] [Full Text] [PDF]

				M. Zareie, E. D. Keuning, P. M. ter Wee, C. G. Schalkwijk, R. H. J. Beelen, and J. van den Born Improved biocompatibility of bicarbonate/lactate-buffered PDF is not related to pH Nephrol. Dial. Transplant., January 1, 2006; 21(1): 208 - 216. [Abstract] [Full Text] [PDF]

				V. Schwenger, C. Morath, A. Salava, K. Amann, Y. Seregin, R. Deppisch, E. Ritz, A. Bierhaus, P. P. Nawroth, and M. Zeier Damage to the Peritoneal Membrane by Glucose Degradation Products Is Mediated by the Receptor for Advanced Glycation End-Products J. Am. Soc. Nephrol., January 1, 2006; 17(1): 199 - 207. [Abstract] [Full Text] [PDF]

				M. Zareie, G.-J. Tangelder, P. M. ter Wee, L. H. Hekking, A. A. van Lambalgen, E. D. Keuning, I. L. Schadee-Eestermans, C. G. Schalkwijk, R. H. Beelen, and J. van den Born Beneficial effects of aminoguanidine on peritoneal microcirculation and tissue remodelling in a rat model of PD Nephrol. Dial. Transplant., December 1, 2005; 20(12): 2783 - 2792. [Abstract] [Full Text] [PDF]

				A LAPOLLA, R FLAMINI, A LUPO, N C ARICỎ, C RUGIU, R REITANO, M TUBARO, E RAGAZZI, R SERAGLIA, and P TRALDI Evaluation of Glyoxal and Methylglyoxal Levels in Uremic Patients under Peritoneal Dialysis Ann. N.Y. Acad. Sci., June 1, 2005; 1043(1): 217 - 224. [Abstract] [Full Text] [PDF]

				S AGALOU, N AHMED, P J THORNALLEY, and A DAWNAY Advanced Glycation End Product Free Adducts Are Cleared by Dialysis Ann. N.Y. Acad. Sci., June 1, 2005; 1043(1): 734 - 739. [Abstract] [Full Text] [PDF]

				M. Zareie, E. D. Keuning, P. M. ter Wee, R. H. J. Beelen, and J. van den Born Peritoneal dialysis fluid-induced changes of the peritoneal membrane are reversible after peritoneal rest in rats Nephrol. Dial. Transplant., January 1, 2005; 20(1): 189 - 193. [Abstract] [Full Text] [PDF]

				S. Nakamura and T. Niwa Pyridoxal Phosphate and Hepatocyte Growth Factor Prevent Dialysate-Induced Peritoneal Damage J. Am. Soc. Nephrol., January 1, 2005; 16(1): 144 - 150. [Abstract] [Full Text] [PDF]

				J. van de Kerkhof, C. G. Schalkwijk, C. J. Konings, E. C. Cheriex, F. M. van der Sande, P. G. Scheffer, P. M. ter Wee, K. M. Leunissen, and J. P. Kooman N {epsilon}-(carboxymethyl)lysine, N {epsilon}-(carboxyethyl)lysine and vascular cell adhesion molecule-1 (VCAM-1) in relation to peritoneal glucose prescription and residual renal function; a study in peritoneal dialysis patients Nephrol. Dial. Transplant., April 1, 2004; 19(4): 910 - 916. [Abstract] [Full Text] [PDF]

				M. Zareie, L. H. P. Hekking, A. G. A. Welten, B. A. J. Driesprong, I. L. Schadee-Eestermans, D. Faict, A. Leyssens, C. G. Schalkwijk, R. H. J. Beelen, P. M. ter Wee, et al. Contribution of lactate buffer, glucose and glucose degradation products to peritoneal injury in vivo Nephrol. Dial. Transplant., December 1, 2003; 18(12): 2629 - 2637. [Abstract] [Full Text] [PDF]

				A. Puig-Kroger, O. Muniz-Pello, R. Selgas, G. Criado, M-A. Bajo, J. A. Sanchez-Tomero, V. Alvarez, G. del Peso, P. Sanchez-Mateos, C. Holmes, et al. Peritoneal dialysis solutions inhibit the differentiation and maturation of human monocyte-derived dendritic cells: effect of lactate and glucose-degradation products J. Leukoc. Biol., April 1, 2003; 73(4): 482 - 492. [Abstract] [Full Text] [PDF]

				A. S. D. Vriese, S. Mortier, and N. H. Lameire Glucotoxicity of the peritoneal membrane: the case for VEGF Nephrol. Dial. Transplant., December 1, 2001; 16(12): 2299 - 2302. [Full Text] [PDF]

Copyright © 1999 by Multimed Inc.